We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
- Authors
Gupta, Anshul; Dai, Yang; Vethanayagam, R Robert; Hebert, Mary F; Thummel, Kenneth E; Unadkat, Jashvant D; Ross, Douglas D; Mao, Qingcheng
- Abstract
Several studies have demonstrated significant interactions between immunosuppressants (e.g., cyclosporin A) and chemotherapeutic drugs that are BCRP substrates (e.g., irinotecan), resulting in increased bioavailability and reduced clearance of these agents. One possible mechanism underlying this observation is that the immunosuppressants modulate the pharmacokinetics of these drugs by inhibiting BCRP. Therefore, the aim of this study was to determine whether the immunosuppressants cyclosporin A, tacrolimus and sirolimus are inhibitors and/or substrates of BCRP.
- Publication
Cancer chemotherapy and pharmacology, 2006, Vol 58, Issue 3, p374
- ISSN
0344-5704
- Publication type
Journal Article
- DOI
10.1007/s00280-005-0173-6